AstraZeneca settles Crestor patent row with generics firms
LONDON, March 25
LONDON, March 25 (Reuters) - AstraZeneca has settled a legal fight over its top-selling cholesterol drug Crestor with generics companies, protecting revenues in the all-important U.S. market until 2016.
Under the agreement, Watson and Egis concede that the Crestor substance patent is valid. The settlement allows Watson to begin selling a generic version of Crestor on May 2, 2016, at a fee to AstraZeneca of 39 percent of net sales, until the end of paediatric exclusivity on July 8, 2016.
AstraZeneca said on Monday its partner Shionogi was also a party to the settlement agreement.
- Islamic State threat 'beyond anything we've seen': Pentagon
- British Muslims blame jihadi subculture after beheading video |
- Israeli air strike kills three Hamas commanders in Gaza |
- U.S. aid workers who survived Ebola leave Atlanta hospital |
- National Guard to withdraw from riot-torn Ferguson, Missouri |